Known targets — ChEMBL curated mechanism
EGFREPHA1EPHA10EPHA2EPHA3EPHA4EPHA5EPHA6EPHA7EPHA8EPHB1EPHB2EPHB3EPHB4EPHB6ERBB2ERBB3ERBB4FLT1FLT4KDRPTK6RETSRCTEK
The experimentally established mechanism targets of Vandetanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.86 |
| ▸ | KDR known ✓ | P35968 | 14/20 | 0.86 |
| ▸ | FLT1 known ✓ | P17948 | 12/20 | 0.86 |
| ▸ | FLT4 known ✓ | P35916 | 12/20 | 0.86 |
| ▸ | EPHA2 known ✓ | P29317 | 3/20 | 0.86 |
| ▸ | EPHB4 known ✓ | P54760 | 3/20 | 0.86 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.86 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.86 |
| ▸ | EPHB6 known ✓ | O15197 | 1/20 | 0.86 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.86 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.86 |
| ▸ | EPHA1 known ✓ | P21709 | 1/20 | 0.86 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 0.86 |
| ▸ | EPHA3 known ✓ | P29320 | 1/20 | 0.86 |
| ▸ | EPHA8 known ✓ | P29322 | 1/20 | 0.86 |
| ▸ | EPHB2 known ✓ | P29323 | 1/20 | 0.86 |
| ▸ | EPHA5 known ✓ | P54756 | 1/20 | 0.86 |
| ▸ | EPHB1 known ✓ | P54762 | 1/20 | 0.86 |
| ▸ | EPHA4 known ✓ | P54764 | 1/20 | 0.86 |
| ▸ | PTK6 known ✓ | Q13882 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vandetanib SCHEMBL29352879 | 0.93 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL28224661 | 0.93 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL9044 | 0.93 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614458 | 0.92 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.92 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3152430 | 0.89 | KDR (0.80) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1783178 | 0.87 | EGFR (0.89) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL27218222 | 0.86 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4544070 | 0.86 | EGFR (0.87) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1614506 | 0.86 | KDR (0.75) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| US-20120252827-A1 | COMBINATION OF THERAPY COMPRISING ZD6474 AND A TAXANE | WEDGE STEPHEN ROBERT (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252826-A1 | Combination Therapy | ASTRAZENECA AB (SE) | 2012-10-04 | — | — | US | disclosed |
| EP-1592423-B1 | COMBINATION THERAPY OF ZD6474 WITH 5-FU AND/OR CPT-11 | ASTRAZENECA AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| US-20100130520-A1 | COMBINATION THERAPY | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| EP-1676845-B1 | New quinazoline derivatives | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1446124-B1 | COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142316-A1 | Combination therapy | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 199/4885KDR 3/4885FLT1 2/4885 |
| US-20120252827-A1 | COMBINATION OF THERAPY COMPRISING ZD6474 AND A TAXANE | ZYX, VEGFA, TEK | EGFR 178/4885KDR 4/4885FLT1 8/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 207/4885KDR 3/4885FLT1 1/4885 |
| US-20120252826-A1 | Combination Therapy | SLC39A11, SLC46A1, VEGFA | EGFR 1642/4885KDR 157/4885FLT1 25/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885FLT1 1/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FLT1 1/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 120/4885KDR 3/4885FLT1 2/4885 |
| US-20100130520-A1 | COMBINATION THERAPY | VEGFA, FLT4, FLT1 | EGFR 1367/4885KDR 24/4885FLT1 3/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FLT1 1/4885 |
| US-20060142316-A1 | Combination therapy | VEGFA, FLT4, FLT1 | EGFR 1367/4885KDR 24/4885FLT1 3/4885 |
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | FLT4, KDR, TEK | EGFR 7/4885KDR 2/4885FLT1 5/4885 |
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ZYX, VEGFA, TEK | EGFR 192/4885KDR 4/4885FLT1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.